Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy

Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy

Abstract Myasthenia gravis (MG) is an autoantibody-mediated autoimmune disorder of the neuromuscular junction. A small subset of patients (<10%) with MG, have autoantibodies targeting muscle-specific tyrosine kinase (MuSK). MuSK MG patients respond well to CD20-mediated B cell depletion therapy (...

Full description

Bibliographic Details
Main Authors: Miriam L. Fichtner, Kenneth B. Hoehn, Easton E. Ford, Marina Mane-Damas, Sangwook Oh, Patrick Waters, Aimee S. Payne, Melissa L. Smith, Corey T. Watson, Mario Losen, Pilar Martinez-Martinez, Richard J. Nowak, Steven H. Kleinstein, Kevin C. O’Connor
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Acta Neuropathologica Communications
Subjects:
Myasthenia gravis
Muscle-specific tyrosine kinase (MuSK)
B cells
Autoantibodies
B cell depletion therapy
Rituximab
Online Access:https://doi.org/10.1186/s40478-022-01454-0

Internet

https://doi.org/10.1186/s40478-022-01454-0

Similar Items